Reading the article on the use of oseltamivir (Tamiflu) for treatment of influenza [BCMJ 2015;57:402-406 [3]] was like revisiting an old nightmare. Worldwide, governments have invested over $9 billion in stockpiling this most controversial drug. The Canadian government spent about $400 million several years ago only to have the stockpile outdate before it was used. Multiple studies attest to the very marginal benefits of this expensive drug.

The article conveniently failed to rationally address the concept of cost-benefit ratio with regard to the use of the drug. Thousands of primary care practitioners have long ago decided the efficacy (or lack thereof) regarding this drug. That is why it is not widely used, as the article points out. Public health dollars could be spent more effectively on other endeavors in my opinion.
—Robert H. Brown, MD
Sidney